Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


April 24, 2015 10:04 PM ET

Healthcare Equipment and Supplies

Company Overview of Ortho-Clinical Diagnostics, Inc.

Company Overview

Ortho-Clinical Diagnostics, Inc. provides solutions for screening, diagnosing, monitoring, and confirming diseases for the transfusion medicine community and laboratories worldwide. It offers integrated clinical chemistry and immunoassay testing systems, chemistry systems, immunodiagnostic systems, and automation solutions that streamline and standardize laboratory workflow. The company also provides donor screening solutions, such as Ortho Summit System, a system for screening assays, automation, and information management; T-cruzi ELISA test system, an enzyme-linked immunosorbant assay for the qualitative detection of antibodies to trypanosoma cruzi in human serum and plasma specimens; and...

1001 US Highway 202

Raritan, NJ 08869

United States

Founded in 1974

Phone:

908-218-8137

Fax:

908-218-8168

Key Executives for Ortho-Clinical Diagnostics, Inc.

Chairman and Chief Executive Officer
Age: 54
Chief Financial Officer
Age: 49
Chief Operating Officer
Executive Vice President for Commercial
General Counsel
Compensation as of Fiscal Year 2014.

Ortho-Clinical Diagnostics, Inc. Key Developments

Ortho-Clinical Diagnostics, Inc. Enters into Distribution and Supply Agreement with Quotient Limited

Ortho-Clinical Diagnostics, Inc. announced it has entered into an exclusive agreement with Quotient Limited to distribute and sell Quotient's transfusion diagnostics platform MosaiQ. MosaiQ, which is currently in development, is being designed with Quotient's proprietary technology platform. This technology promises to allow improved time to test results and more comprehensive matching of donor and patient blood, beyond what is available in current transfusion diagnostic instruments. Under the terms of the Distribution and Supply Agreement, Quotient is responsible for the development and launch of MosaiQ, while OCD will leverage its worldwide commercial capabilities to sell the product to customers. OCD has exclusive rights to distribute MosaiQ for the global patient testing market (for blood grouping) and the donor testing market in the developing world and Japan (for blood grouping and serological disease screening). Quotient will be responsible for the manufacture of all products (instruments, consumables and ancillary products) associated with MosaiQ and has retained all other commercial rights to MosaiQ with OCD receiving a right of first offer where Quotient decides to commercialize MosaiQ with a third party for an application other than blood grouping. The agreement also allows Quotient and OCD to explore opportunities to develop and commercialize MosaiQ for other diagnostics applications outside of patient testing and donor screening.

Ortho-Clinical Diagnostics, Inc. Introduces NEPHROCHECK Test System

Ortho-Clinical Diagnostics, Inc. announced the nationwide availability to hospitals of the NEPHROCHECK Test System designed to help healthcare providers identify patients at risk of developing moderate or severe acute kidney injury (AKI) within 12 hours of patient assessment. The NEPHROCHECK Test System detects the presence of insulin-like growth-factor binding protein (IGFBP-7) and tissue inhibitor of metalloproteinases (TIMP-2) in the urine, which are associated with AKI. Within 20 minutes, the test provides a score based on the amount of the proteins present that correlates to the patients risk of developing AKI within 12 hours of the test being performed. Patients with a positive NEPHROCHECK AKIRisk Score (greater than the cutoff of 0.3) have a one in four to a one in three chance of developing moderate or severe AKI within 12 hours of assessment. The NEPHROCHECK® Test System is intended to be used in conjunction with clinical evaluation in patients who currently have or have had within the past 24 hours acute cardiovascular and or respiratory compromise and are ICU patients as an aid in the risk assessment for moderate or severe AKI within 12 hours of patient assessment. The NEPHROCHECK® Test System is intended to be used in patients 21 years of age or older.

Ortho-Clinical Diagnostics, Inc. Receives CE Mark for ORTHO VISION(TM) Analyzer to Take Full Automation Transfusion Medicine Testing to Next Level

Ortho-Clinical Diagnostics, Inc. announced that it obtained CE Mark (Conformité Européenne) for the ORTHO VISION(TM) Analyzer, a highly interactive, fully automated analyzer for transfusion medicine laboratories. The ORTHO VISION(TM) Analyzer for ORTHO Column Agglutination Technologies will be commercially available in Europe, Japan and Australia Fourth Quarter 2014. Transfusion medicine has evolved to enhance safety and establish critical efficiencies, although today's automation solutions lack the ability to anticipate and respond to individual user needs and ever-changing conditions within the laboratory. The introduction of the ORTHO VISION(TM) Analyzer represents an advanced system able to meet these needs through automation that is responsive, the next evolution in transfusion medicine. Designed with secure monitoring technologies for responsive safety checks and balances, the ORTHO VISION(TM) Analyzer gives transfusion medicine professionals the ability to track every critical automated step in the immunohematology testing process. Through Ortho Clinical Diagnostics' proprietary IntelliCheck(R) Technology, the ORTHO VISION(TM) Analyzer verifies and documents diagnostic checks throughout the sampling process; while e-Connectivity provides 24/7 remote data tracking that monitors and ensures instrument performance while maximizing uptime. Laboratory personnel can also log on anytime, anywhere to collaborate on interpreting results in real time for an extra level of confidence. In addition to multiple safety advancements, the ORTHO VISION(TM) Analyzer also delivers dynamic workflow management, providing the adaptability to respond to unpredictable lab demand. Now lab personnel will be able to focus on prioritizing tests as they are requested, including STAT requests, making informed decisions and re-establishing a natural flow in the lab, all while automating more tests than ever before. Building on its market leadership position, Ortho Clinical Diagnostics is reinforcing its commitment to the transfusion medicine industry with innovations such as the ORTHO VISION(TM) Analyzer, designed to meet the needs of labs and their patients.

Similar Private Companies By Industry

Company Name Region
T.P. Orthodontics, Inc. United States
Smart Caregiver Corporation United States
CIS Biotech, Inc. United States
Orchid Keller United States
Captiva Spine, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Ortho-Clinical Diagnostics, Inc., please visit www.orthoclinical.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.